Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events

BenzingaJul 26 10:21 ET

Ahead of the Bank of Japan meeting, there continues to be selling pressure from position adjustments.

The Nikkei Average fell for 8 consecutive business days. Trading ended at 37,667.41 yen (-202.10 yen) (with a volume of approximately 1.708 billion shares) . Reflecting the trend of high-tech stocks being sold in the previous day's US market, the Nikkei Average started to decline. However, after falling more than 3,400 yen for the previous 7 business days, it rebounded autonomously from buying and rose up to 38,105.96 yen at the end of the morning session. However, we still need to confirm the performance trends of major domestic companies that are beginning to ramp up, and next week will also see the Bank of Japan's monetary policy decision-making meeting.

Fisco JapanJul 26 02:58 ET

The Nikkei average fell for the 8th consecutive day, with semiconductor and Toyota Motor stocks dropping sharply in the afternoon.

On the 25th, the US stock market was mixed. The Dow Jones Industrial Average closed at 39,935.07, up 81.20 points (+0.20%), the NASDAQ closed at 17,181.73, down 160.68 points (-0.93%), and the S&P 500 closed at 5,399.22, down 27.91 points (-0.51%). Risk aversion remained strong, and the market was mixed after the opening. However, due to the better-than-expected growth in domestic gross domestic product (GDP) and consumption in the April-June period, pessimistic views on the economy have retreated, leading to buying back.

Fisco JapanJul 26 02:30 ET

The clinical trial results of the myopia progression suppression device at Pingtian Lab are scheduled to be announced around spring 2026.

Pitada Lab <4890> is a bioventure originating from Keio University that develops medical devices using violet light with expected effects on inhibiting myopia progression and brain activation, as well as pharmaceuticals. It was listed on the Tokyo Stock Exchange Growth Market in June 2022. Its mission is to make the future happy with 'VISIONary INNOVATION', with the goal of creating groundbreaking innovation for myopia, dry eye, presbyopia, and brain diseases. Near.

Fisco JapanJul 26 00:34 ET

Chugai Pharma, Kansai Paint, etc. (added) Rating

Upgrade - Bullish Code | Company Name | Securities Company | Conventional | After the change | ------ | --------------- | ---------- | ------- | ------- | <3436> | SUMCO | Daiwa | "3" | "2" | Target share price change code | Company Name | Securities Company | Conventional | After the change | ------ | --------------- | ---------- | -------

Fisco JapanJul 25 22:23 ET

Chordia Therapeutics, Simbio Pharmaceuticals, etc.

<190A> Chordia Therapeutics Co., Ltd. SBI Investment Co., Ltd. shareholding ratio 6.42% → 8.73% Reporting obligation start date 2024/07/18 <202A> Mamezou Digital Holdings Co., Ltd. Mamezou K2 Top Holdings Co., Ltd. shareholding ratio 71.78% → 67.99% Reporting obligation start date 2024/07/24 <2164> Regional Newspaper Co., Ltd. Engi Co., Ltd.

Fisco JapanJul 25 19:35 ET